RCUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Arcus Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$22.14+0.02 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $2.79B
- P/E (TTM)
- –
- Dividend yield
- –
Arcus Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Market Cap | $2.82B | $197.05M |
| Enterprise Value | $2.12B | $106.56M |
| PS Ratio | 24.10 | 3.93 |
| PB Ratio | 6.08 | 2.14 |
| P/TBV Ratio | 6.08 | 2.46 |
Enterprise value
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| EV / Sales | 18.10 | 2.69 |
Income (trailing twelve months)
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Revenue | $117.00M | $57.94M |
| Operating Income | -$486.00M | -$21.44M |
| Pretax Income | -$460.00M | -$14.45M |
| Net Income | -$460.00M | -$22.46M |
| EBITDA | -$476.00M | -$16.91M |
| EPS (Diluted) | -$3.90 | -$0.83 |
Margins
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Operating Margin | -415.4% | -44.5% |
| Pretax Margin | -393.2% | -13.0% |
| Profit Margin | -393.2% | -39.2% |
| EBITDA Margin | -406.8% | -31.3% |
| FCF Margin | -406.0% | -8.85% |
Returns
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -90.8% | -53.1% |
| Return on Assets (ROA) | -46.0% | -41.0% |
| Return on Capital Employed (ROCE) | -66.9% | -37.8% |
Growth
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -55.3% | 6.01% |
| Revenue Growth (3Y CAGR) | 30.2% | 2.25% |
| Revenue Growth (5Y CAGR) | 25.9% | 6.42% |
Balance sheet
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $702.00M | $62.42M |
| Net Cash (Debt) | $702.00M | $15.68M |
| Net Cash Per Share | $5.51 | $0.65 |
| Equity (Book Value) | $464.00M | $48.79M |
| Book Value Per Share | $3.64 | $1.36 |
| Tangible Book Value | $464.00M | $23.06M |
| Working Capital | $558.00M | $75.77M |
Financial position
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Current Ratio | 3.82 | 3.30 |
| Quick Ratio | 3.55 | 2.39 |
| Interest Coverage | -44.18 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$474.00M | -$12.35M |
| Capital Expenditures | -$1.00M | -$1.06M |
| Free Cash Flow | -$475.00M | -$20.28M |
| FCF Per Share | -$3.73 | -$0.41 |
Efficiency
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 0.12 | 0.38 |
| Revenue Per Employee | $194.68K | $398.96K |
| Profits Per Employee | -$765.39K | -$732.08K |
| Employee Count | 601 | 73 |
Dividends and yields
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -16.3% | -21.2% |
| FCF Yield | -16.8% | -7.64% |
| Buyback Yield | -10.2% | -0.58% |
| Shareholder Yield | -10.2% | 0.00% |
Shares
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 127,333,000 | 59,128,900 |
| Shares Change (YoY) | 22.8% | 11.1% |
| Shares Change (QoQ) | 1.20% | 0.54% |
| Float | 86,928,500 | 48,744,500 |
| Shares Held by Insiders | 31.7% | 11.8% |
| Shares Held by Institutions | 96.3% | 59.4% |
Taxes
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Arcus Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | 0.21 | 0.10 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Arcus Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.